P450 Enzyme Substrate/Inhibitor Prediction
Graph Attention Networks 
Multi-Isoform Profiling 
In Vitro Metabolic Validation CYP450 enzymes metabolize over 75% of drugs. Our platform deploys graph attention networks to predict substrate affinity and inhibition across five major isoforms—validated through human liver microsome and recombinant enzyme kinetics.
Why P450 Prediction Is the Critical Gate for Pharmacokinetic Safety?
A seed-stage biotech optimizing a CNS compound cannot afford a CYP2D6 liability that excludes 7% of Caucasian patients. A pharma team advancing a polypharmacy candidate needs confidence that co-administration with statins or anticoagulants will not trigger CYP3A4 or CYP2C9-mediated DDIs. Static rule-based alerts (e.g., SMARTCyp) identify reactive sites but miss isoform-specific affinity and polymorphic variability. Our AI models predict substrate/inhibitor classification with isoform resolution, attention-weighted interpretability, and direct metabolic validation—delivering pharmacokinetic risk assessments that guide dose optimization and clinical trial design before first-in-human.
What Sets the Metabolism Platform Apart
Graph Attention Networks
GAT models process molecular graphs with attention mechanisms, achieving >0.90 AUC on CYP3A4/2D6 inhibition benchmarks and highlighting atoms driving metabolic liability.
Multi-Isoform Profiling
Simultaneous prediction across CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 with polymorphic allele sensitivity scoring for precision dosing.
Metabolic Validation Loop
Predictions proceed to human liver microsome (HLM) stability assays and recombinant CYP enzyme kinetics for Km/Ki determination, closing the computational-experimental loop.
The P450 Prediction Suite
Substrate Prediction & Clearance Profiling
Predict Phase I Metabolic Fate and Hepatic Clearance
- Isoform-Specific Substrate Classification — Multi-label graph neural networks predict which of the five major CYPs will oxidize a compound, enabling reaction phenotyping without experimental probe cocktails.
- Site of Metabolism (SoM) Prediction — Attention-guided SoM mapping identifies the most probable oxidation locus (aliphatic hydroxylation, aromatic oxidation, N-dealkylation), guiding metabolite structure elucidation.
- Polymorphic Sensitivity Scoring — CYP2D6 poor-metabolizer and CYP2C19 ultra-rapid metabolizer allele frequency weighting for population pharmacokinetic risk assessment.
For virtual biotechs without ADMET infrastructure, substrate prediction eliminates costly reaction phenotyping experiments. For pharma, SoM prediction accelerates metabolite identification and MIST (Metabolites in Safety Testing) compliance.
Inhibitor Prediction & DDI Risk Assessment
Quantify Perpetrator Potential and Co-Medication Risk
- Reversible Inhibition Profiling — IC₅₀ prediction for competitive inhibition across all five isoforms, with mechanism-based inhibition (MBI) flagging for time-dependent inactivators.
- DDI Risk Matrix — Perpetrator-victim interaction scoring against common co-medications (statins, anticoagulants, antiarrhythmics) with clinical relevance thresholds.
- Induction Potential Screening — PXR and CAR nuclear receptor activation prediction for CYP3A4 and CYP1A2 induction liability.
When combined with Microsomal Stability Prediction, inhibitor predictions enable full DDI risk assessment for regulatory submission (FDA/EMA DDI guidance).
Metabolite Structure Prediction & Bioactivation Risk
Predict Metabolite Identity and Reactive Intermediate Formation
- Phase I Metabolite Generation — Rule-based and AI-hybrid metabolite prediction engines enumerate likely oxidation, reduction, and hydrolysis products.
- Reactive Metabolite Flagging — Identification of soft electrophiles, quinones, and acyl glucuronide precursors with covalent binding risk scoring.
- Bioactivation Pathway Mapping — Tracing of prodrug activation (e.g., tamoxifen → 4-hydroxytamoxifen) and toxic metabolite formation (e.g., acetaminophen → NAPQI).
For Lead Optimization teams, metabolite prediction guides structural modifications to block bioactivation while preserving efficacy. For regulatory affairs, reactive metabolite flagging supports MIST and safety pharmacology dossiers.
Platform Instrumentation
| Software / System | Core Capability |
|---|---|
| PyTorch Geometric / DGL | Graph attention network training and molecular graph embedding for CYP interaction prediction. |
| ADMETlab 2.0 / DeepCYPs | Multi-task graph attention framework for CYP inhibition and substrate classification across five isoforms. |
| SMARTCyp / FAME 3 | Site-of-metabolism prediction with 2D and 3D reactivity models for CYP-mediated oxidation. |
| HLM Stability Assay | Human liver microsome intrinsic clearance (CLint) determination for substrate validation. |
| Recombinant CYP Enzymes | Km, Vmax, and Ki determination for individual isoforms (1A2, 2C9, 2C19, 2D6, 3A4). |
| CYP Induction Reporter Assay | PXR and CAR activation screening for CYP3A4 and CYP1A2 induction potential. |
| CDD Vault / Dotmatics | ELN-integrated data management and handoff to ADMET Prediction & Modeling. |
Standardized Workflow
Project Workflow
A standardized, milestone-driven execution system. From compound structure ingestion to in vitro validation and handoff—managed by a single computational project team, tracked in real time.
01 Data Ingestion & Curation
- Receive compound structures (SMILES/SDF). Standardize, assign stereochemistry, and query ChEMBL/PubChem for known CYP data.
Deliverable: Curated dataset + known CYP interaction report.
02 Model Training & SoM Prediction
- Train GAT ensemble on curated inhibition/substrate datasets. Predict SoM with attention-weighted atom contributions.
Deliverable: SoM prediction map + attention visualization.
03 Inhibitor/Substrate Classification
- Deploy multi-isoform classification for all five CYPs. Flag MBI potential and time-dependent inhibition.
Deliverable: Isoform-specific inhibition/substrate classification with confidence scores.
04 DDI Risk & Metabolite Analysis
- Generate DDI risk matrix against common co-medications. Predict metabolite structures and flag reactive intermediates.
Deliverable: DDI risk matrix + metabolite prediction report with bioactivation flags.
05 In Vitro Validation & Handoff
- Validate predictions via HLM CLint and recombinant CYP kinetics. Handoff to ADMET Prediction & Modeling or Lead Optimization.
Deliverable: In vitro validation data + PK risk assessment + transition plan.
Sample Requirements
| Requirement | Details |
|---|---|
| Compound structures | SMILES or SDF format; 1–10,000+ compounds accepted |
| Known metabolism data | Internal HLM CLint, recombinant CYP Km/Ki, or reaction phenotyping results (optional) |
| Co-medication context | Target patient population and likely concomitant medications for DDI risk assessment |
| Project scope | Early triage, lead optimization support, or regulatory submission (FDA/EMA DDI guidance) |
| Polymorphic focus | CYP2D6 or CYP2C19 polymorphic sensitivity if precision dosing required |
Standard Deliverables
- Isoform-specific substrate/inhibitor classification with GAT confidence scores
- Site-of-metabolism prediction with attention-weighted atom contributions
- DDI perpetrator-victim risk matrix with clinical relevance thresholds
- Metabolite structure prediction and reactive metabolite risk flagging
- Polymorphic sensitivity scoring for CYP2D6 and CYP2C19 (if requested)
- Electronic data package for ADMET Prediction & Modeling integration
- Direct handoff to HLM stability assay, recombinant CYP kinetics, or Lead Optimization
Frequently Asked Questions
Case Study
Case Study: GTransCYPs — Graph Transformer Models for Major CYP Isoform Prediction
Published Evidence:
Abdelwahab AA. Advancing ADMET prediction for major CYP450 isoforms: graph-based models, limitations, and future directions. BioMed Eng OnLine. 2025;24:66.
Key Findings:
- Graph-based models (GNNs, GCNs, GATs) have achieved >0.90 AUC on CYP3A4 and CYP2D6 inhibition prediction, with attention mechanisms highlighting pharmacophore atoms responsible for isoform selectivity.
- Multi-task learning frameworks (ADMETlab 2.0, DeepCYPs) simultaneously predict inhibition and substrate classification across five isoforms, outperforming single-task models through shared representation learning.
- Hybrid approaches combining graph-based fingerprints with molecular descriptors (CatBoost ensemble) demonstrated superior generalization on CYP inhibition tasks compared to pure deep learning models.
- Explainable AI techniques (SHAP, integrated gradients) identified catechol groups and basic nitrogen atoms as key CYP2C9 inhibition drivers, providing actionable medicinal chemistry insights.
Industrial Translation:
The review demonstrates that graph attention networks have matured into reliable tools for CYP interaction prediction, with attention mechanisms providing interpretability critical for regulatory acceptance. For seed-stage biotechs, this eliminates the need for expensive probe-cocktail reaction phenotyping in early triage. For pharma teams, multi-task GAT models enable simultaneous DDI risk assessment across all major isoforms, accelerating IND-enabling ADMET packages. Our platform operationalizes this peer-reviewed paradigm by integrating GAT predictions with HLM stability assays and recombinant CYP kinetics, delivering metabolism-ready compound profiles from design to development.
Figure 1. Study overview covering CYP enzymes, graph-based modeling, GNN and XAI advances in ADMET prediction, DDI/DTI insights, data sources, and future directions. (Abdelwahab AA, et al., 2025)
Reference
- Abdelwahab AA. Advancing ADMET prediction for major CYP450 isoforms: graph-based models, limitations, and future directions. BioMed Eng OnLine. 2025;24:66.
Need AI-enhanced P450 enzyme prediction to de-risk your pharmacokinetic profile? Our team can design a customized metabolism assessment pipeline tailored to your target population, co-medication landscape, and regulatory milestones. Contact our scientific team today.
